BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169. [PMID: 19755969 DOI: 10.1038/ajg.2009.545] [Cited by in Crossref: 344] [Cited by in F6Publishing: 347] [Article Influence: 26.5] [Reference Citation Analysis]
Number Citing Articles
1 Liefferinckx C, Hubert A, Thomas D, Bottieau J, Minsart C, Cremer A, Amininejad L, Vallée F, Toubeau JF, Franchimont D. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease. Dig Liver Dis 2022:S1590-8658(22)00617-X. [PMID: 35977875 DOI: 10.1016/j.dld.2022.07.015] [Reference Citation Analysis]
2 Kim MC, Kim SH, Koh SJ, Park JH, Yoon H. Clinical implication of radiologic complete remission on Crohn's Disease: Compared with endoscopic remission. Eur J Radiol 2022;155:110469. [PMID: 35988393 DOI: 10.1016/j.ejrad.2022.110469] [Reference Citation Analysis]
3 Han W, Wu J, Zhang P, Hu N, Mei Q, Hu J. Fecal calprotectin predicts endoscopic activity and mucosal healing of small bowel Crohn's disease evaluated by double-balloon endoscopy. Int J Colorectal Dis 2022. [PMID: 35927341 DOI: 10.1007/s00384-022-04232-5] [Reference Citation Analysis]
4 Chiarello MM, Pepe G, Fico V, Bianchi V, Tropeano G, Altieri G, Brisinda G. Therapeutic strategies in Crohn’s disease in an emergency surgical setting. World J Gastroenterol 2022; 28(18): 1902-1921 [DOI: 10.3748/wjg.v28.i18.1902] [Reference Citation Analysis]
5 Vaghari-Tabari M, Targhazeh N, Moein S, Qujeq D, Alemi F, Majidina M, Younesi S, Asemi Z, Yousefi B. From inflammatory bowel disease to colorectal cancer: what's the role of miRNAs? Cancer Cell Int 2022;22:146. [PMID: 35410210 DOI: 10.1186/s12935-022-02557-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Matar M, Levi R, Zvuloni M, Shamir R, Assa A. Pediatric inflammatory bowel disease: Fecal calprotectin response to Anti-tumor necrosis factor alpha. Pediatr Res 2022. [PMID: 35379929 DOI: 10.1038/s41390-022-02045-4] [Reference Citation Analysis]
7 Mitchel EB, Rosh JR. Pediatric Management of Crohn’s Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.013] [Reference Citation Analysis]
8 Maldonado-Contreras A. Food as Treatment of Inflammatory Bowel Diseases. Infect Immun 2022;:e0058321. [PMID: 35323020 DOI: 10.1128/iai.00583-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Reference Citation Analysis]
10 Lerang F, Holst R, Henriksen M, Wåhlberg H, Jelsness-jørgensen L. Antitumour necrosis factor alpha treatment in Crohn’s disease: long-term efficacy, side effects and need for surgery. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2022.2042592] [Reference Citation Analysis]
11 Metwaly A, Reitmeier S, Haller D. Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nat Rev Gastroenterol Hepatol. [DOI: 10.1038/s41575-022-00581-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
12 Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease. Aliment Pharmacol Ther 2022. [PMID: 35166396 DOI: 10.1111/apt.16805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Forlano R, Mullish BH, Roberts LA, Thursz MR, Manousou P. The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:662. [PMID: 35054847 DOI: 10.3390/ijms23020662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022:S0016-5085(21)04072-5. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
15 Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E, Rydzewska G. Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz Gastroenterol 2021;16:257-96. [PMID: 34976235 DOI: 10.5114/pg.2021.110914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Tetangco EP, Stein AC. Medical Treatment of Intestinal Crohn's disease. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100862] [Reference Citation Analysis]
17 Adler J, Eder SJ, Gebremariam A, Moran CJ, Bass LM, Moses J, Lewis JD, Singer AAM, Morhardt TL, Picoraro JA, Cardenas V, Zacur GM, Colletti RB. Quantification of Mucosal Activity from Colonoscopy Reports via the Simplified Endoscopic Mucosal Assessment for Crohn's Disease. Inflamm Bowel Dis 2021:izab315. [PMID: 34964861 DOI: 10.1093/ibd/izab315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Lefevre PLC, Dulai PS, Wang Z, Guizzetti L, Feagan BG, Pop A, Yassine M, Shackelton LM, Jairath V, Sandborn WJ, Vande Casteele N. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs 2021. [PMID: 34951696 DOI: 10.1007/s40259-021-00512-8] [Reference Citation Analysis]
19 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Nguyen MTT, Ali A, Bodkin RP. Small Bowel Volvulus as Delayed Presentation of Undiagnosed Crohn's Disease: A Case Report. Clin Pract Cases Emerg Med 2021;5:455-8. [PMID: 34813443 DOI: 10.5811/cpcem.2021.8.53524] [Reference Citation Analysis]
21 Yin J, Tong F, Ye Y, Hu T, Xu L, Zhang L, Zhu J, Pang Z. Hsa_circRNA_103124 Upregulation in Crohn's Disease Promotes Cell Proliferation and Inhibits Autophagy by Regulating the Hsa-miR-650/AKT2 Signaling Pathway. Front Genet 2021;12:753161. [PMID: 34804121 DOI: 10.3389/fgene.2021.753161] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Gubatan J, Holman DR, Puntasecca CJ, Polevoi D, Rubin SJ, Rogalla S. Antimicrobial peptides and the gut microbiome in inflammatory bowel disease. World J Gastroenterol 2021; 27(43): 7402-7422 [PMID: 34887639 DOI: 10.3748/wjg.v27.i43.7402] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
23 Tao Y, Li H, Xu H, Tang W, Fan G, Yang X. Can the simplified magnetic resonance index of activity be used to evaluate the degree of activity in Crohn's disease? BMC Gastroenterol 2021;21:409. [PMID: 34711180 DOI: 10.1186/s12876-021-01987-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Adler J, Eder SJ, Gebremariam A, French KR, Moncion I, Singer AAM, Bass LM, Moran CJ, Picoraro JA, Moses J, Lewis JD, Sandberg KC, Mar SJ, Ebach DR, Saeed SA, Rosh JR, Neef HC, Kaplan JL, Goyal A, Del Rosario JF, Zacur GM. Development and Testing of a New Simplified Endoscopic Mucosal Assessment for Crohn's Disease: The SEMA-CD. Inflamm Bowel Dis 2021;27:1585-92. [PMID: 33382069 DOI: 10.1093/ibd/izaa307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sævik F, Eriksen R, Eide GE, Gilja OH, Nylund K. Development and Validation of a Simple Ultrasound Activity Score for Crohn's Disease. J Crohns Colitis 2021;15:115-24. [PMID: 32504533 DOI: 10.1093/ecco-jcc/jjaa112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
26 Bakkaloglu OK, Eskazan T, Celik S, Kurt EA, Hatemi I, Erzin Y, Celik AF. Can we predict mucosal remission in ulcerative colitis more precisely with a redefined cutoff level of C-reactive protein? Colorectal Dis 2021. [PMID: 34610199 DOI: 10.1111/codi.15940] [Reference Citation Analysis]
27 Yang RX, Song WJ, Wu ZQ, Goyal H, Xu HG. Association of Serum Neuron-Specific Enolase and C-Reactive Protein With Disease Location and Endoscopic Inflammation Degree in Patients With Crohn's Disease. Front Med (Lausanne) 2021;8:663920. [PMID: 34513858 DOI: 10.3389/fmed.2021.663920] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones G, Lees CW. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:1835-1844.e6. [DOI: 10.1016/j.cgh.2020.08.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
29 Yong HM, Park SJ, Jeon SR, Park H, Kim HG, Lee TH, Park J, Kim JO, Lee JS, Ko BM, Goong HJ, Park S. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. Medicine (Baltimore) 2021;100:e27065. [PMID: 34449501 DOI: 10.1097/MD.0000000000027065] [Reference Citation Analysis]
30 Scapaticci M, Bartolini A, Biscaro M, Biscaro R, Da Rin G. Interleukin-6 and Serum/Fecal Calprotectin as Useful Specific Markers for Monitoring Rheumatic Diseases: A Pilot Study. Lab Med 2021:lmab034. [PMID: 34405886 DOI: 10.1093/labmed/lmab034] [Reference Citation Analysis]
31 Eckard AR, Hughes HY, Hagood NL, O'Riordan MA, Labbato D, Kosco JC, Scott SE, McComsey GA. Fecal Calprotectin Is Elevated in HIV and Related to Systemic Inflammation. J Acquir Immune Defic Syndr 2021;86:231-9. [PMID: 33065582 DOI: 10.1097/QAI.0000000000002538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Witges K, Sexton K, Graff LA, Targownik LE, Lix LM, Haviva C, Stone J, Shafer LA, Vagianos K, Bernstein CN. What Is a Flare? The Manitoba Living With IBD Study. Inflamm Bowel Dis 2021:izab192. [PMID: 34347048 DOI: 10.1093/ibd/izab192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Noh SM, Oh EH, Park SH, Lee JB, Kim JY, Park JC, Kim J, Ham NS, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy. J Crohns Colitis 2020;14:1231-40. [PMID: 32157278 DOI: 10.1093/ecco-jcc/jjaa042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
34 Norsa L, Ferrari A, Arrigo S, Bramuzzo M, Deganello Saccomani M, Di Nardo G, Illiceto MT, Miele E, Paci M, Romano C, Romeo E, Daperno M, Oliva S; Endoscopy group of the Italian society of pediatric Gastroenterology Hepatology and Nutrition (SIGENP). Scoring Endoscopy in Pediatric Inflammatory Bowel Disease: A Way to Improve Quality. J Pediatr Gastroenterol Nutr 2021;73:48-53. [PMID: 33720096 DOI: 10.1097/MPG.0000000000003090] [Reference Citation Analysis]
35 van Haaften WT, Mortensen JH, Dige AK, Grønbæk H, Hvas CL, Bay-Jensen AC, Karsdal MA, Olinga P, Manon-Jensen T, Dijkstra G. Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study. Clin Transl Gastroenterol 2020;11:e00217. [PMID: 33094957 DOI: 10.14309/ctg.0000000000000217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Wong ECL, Buffone E, Lee SJ, Dulai PS, Marshall JK, Reinisch W, Narula N. End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease. J Crohns Colitis 2021;15:1114-9. [PMID: 33245751 DOI: 10.1093/ecco-jcc/jjaa242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
37 Walshe M, Borowski K, Battat R, Hudesman D, Wolf DC, Okada L, Jain A, Silverberg MS. Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index. Crohn's & Colitis 360 2021;3:otab032. [DOI: 10.1093/crocol/otab032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Schaefer M, Laurent V, Grandmougin A, Vuitton L, Bourreille A, Luc A, Clerc-Urmes I, Orry X, Frampas E, De Billy M, Pouillon L, Le Berre C, Gay C, Meyer J, Baumann C, Peyrin-Biroulet L. A Magnetic Resonance Imaging Index to Predict Crohn's Disease Postoperative Recurrence: The MONITOR Index. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00699-6. [PMID: 34216820 DOI: 10.1016/j.cgh.2021.06.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Yasutomi E, Inokuchi T, Hiraoka S, Takei K, Igawa S, Yamamoto S, Ohmori M, Oka S, Yamasaki Y, Kinugasa H, Takahara M, Harada K, Furukawa M, Itoshima K, Okada K, Otsuka F, Tanaka T, Mitsuhashi T, Kato J, Okada H. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci Rep 2021;11:11086. [PMID: 34045529 DOI: 10.1038/s41598-021-90441-x] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
40 Mak LY, Tong TSM, Cheung KS, Chen LJ, Lui KL, Lau KS, Leung WK. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020;11:e00138. [PMID: 32132451 DOI: 10.14309/ctg.0000000000000138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
41 Cordes F, Demmig C, Bokemeyer A, Brückner M, Lenze F, Lenz P, Nowacki T, Tepasse P, Schmidt HH, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.Clin Transl Gastroenterol. 2020;11:e00134. [PMID: 32352717 DOI: 10.14309/ctg.0000000000000134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Jere M, Garrick V, Curtis L, Tayler R, Gervais L, Gerasimidis K, Hansen R. Point-of-care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic. BMJ Open Gastroenterol 2021;8:e000631. [PMID: 33947712 DOI: 10.1136/bmjgast-2021-000631] [Reference Citation Analysis]
43 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
44 Liu A, Lv H, Tan B, Shu H, Yang H, Li J, Qian J. Accuracy of the highly sensitive C-reactive protein/albumin ratio to determine disease activity in inflammatory bowel disease. Medicine (Baltimore) 2021;100:e25200. [PMID: 33832080 DOI: 10.1097/MD.0000000000025200] [Reference Citation Analysis]
45 Wilkens R, Novak KL, Maaser C, Panaccione R, Kucharzik T. Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. Therap Adv Gastroenterol 2021;14:17562848211006672. [PMID: 33948115 DOI: 10.1177/17562848211006672] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
46 Osredkar J, Kurent T, Fabjan T, Kumer K, Božnar Alič E, Drobne D. The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. Biochem Med (Zagreb) 2021;31:020707. [PMID: 33927557 DOI: 10.11613/BM.2021.020707] [Reference Citation Analysis]
47 Yu Y, Zhao H, Luo Y, Lou J, Chen J, Fang Y. Poor Concordance Between Clinical Activity and Endoscopic Severity in Pediatric Crohn's Disease: Before and After Induction Therapy. Dig Dis Sci. 2021;. [PMID: 33818661 DOI: 10.1007/s10620-021-06917-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Burisch J, Zhang H, Choong CK, Nelson D, Naegeli A, Gibble T, Goetz I, Egeberg A. Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease. Therap Adv Gastroenterol 2021;14:17562848211004841. [PMID: 33868458 DOI: 10.1177/17562848211004841] [Reference Citation Analysis]
49 Zhou FS, Gao N, Sun X, Jiang XY, Chen JJ, Mao QQ, Zhong L. C-reactive protein/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: A retrospective study. Medicine (Baltimore) 2021;100:e24925. [PMID: 33725853 DOI: 10.1097/MD.0000000000024925] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
50 Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn's Disease during One-Year Follow-Up. Nutrients 2021;13:1083. [PMID: 33810258 DOI: 10.3390/nu13041083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. J Crohns Colitis 2021;15:462-70. [PMID: 32931556 DOI: 10.1093/ecco-jcc/jjaa189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
52 Yamanashi K, Katsurada T, Nishida M, Onishi R, Omotehara S, Otagiri S, Sakurai K, Nagashima K, Kinoshita K, Takagi R, Sakamoto N. Crohn's Disease Activity Evaluation by Transabdominal Ultrasonography: Correlation with Double-Balloon Endoscopy. J Ultrasound Med 2021. [PMID: 33595133 DOI: 10.1002/jum.15645] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
53 Lobo A, Torrejon Torres R, McAlindon M, Panter S, Leonard C, van Lent N, Saunders R. Economic analysis of the adoption of capsule endoscopy within the British NHS. Int J Qual Health Care 2020;32:332-41. [PMID: 32395758 DOI: 10.1093/intqhc/mzaa039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
54 Effenberger M, Reider S, Waschina S, Bronowski C, Enrich B, Adolph TE, Koch R, Moschen AR, Rosenstiel P, Aden K, Tilg H. Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients. J Crohns Colitis 2021;15:88-98. [PMID: 32687146 DOI: 10.1093/ecco-jcc/jjaa152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
55 Liu F, Lee SA, Riordan SM, Zhang L, Zhu L. Global Studies of Using Fecal Biomarkers in Predicting Relapse in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:580803. [PMID: 33392214 DOI: 10.3389/fmed.2020.580803] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
56 Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
57 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
58 Buisson A, Mak WY, Andersen MJ, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT. Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis 2021;27:1008-16. [PMID: 33107563 DOI: 10.1093/ibd/izaa269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Soleymani S, Moradkhani A, Eftekhari M, Rahmanian F, Moosavy SH. Correlation between Clinical Symptoms and Lab Tests with Endoscopic Severity Indexes in Patients with Inflammatory Bowel Diseases. Middle East J Dig Dis 2020;12:162-70. [PMID: 33062221 DOI: 10.34172/mejdd.2020.178] [Reference Citation Analysis]
60 Shodeinde AB, Murphy AC, Oldenkamp HF, Potdar AS, Ludolph CM, Peppas NA. Recent Advances in Smart Biomaterials for the Detection and Treatment of Autoimmune Diseases. Adv Funct Mater 2020;30:1909556. [PMID: 33071713 DOI: 10.1002/adfm.201909556] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
61 Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta 2020;510:556-65. [PMID: 32818491 DOI: 10.1016/j.cca.2020.08.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
62 Candia R, Bravo-Soto GA, Monrroy H, Hernandez C, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2020;8:CD012328. [PMID: 32746500 DOI: 10.1002/14651858.CD012328.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterol Hepatol 2021;44:87-95. [PMID: 32680729 DOI: 10.1016/j.gastrohep.2020.04.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Zittan E, Gralnek IM, Berns MS. The New Proactive Approach and Precision Medicine in Crohn's Disease. Biomedicines 2020;8:E193. [PMID: 32635316 DOI: 10.3390/biomedicines8070193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
65 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
66 Pang Y, Ruan H, Wu D, Lang Y, Sun K, Xu C. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy Asthma Clin Immunol 2020;16:37. [PMID: 32477415 DOI: 10.1186/s13223-020-00433-1] [Reference Citation Analysis]
67 Khalaf A, Hoad CL, Menys A, Nowak A, Radford S, Taylor SA, Latief K, Lingaya M, Falcone Y, Singh G, Spiller RC, Gowland PA, Marciani L, Moran GW. Gastrointestinal peptides and small-bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn's disease. Am J Clin Nutr 2020;111:131-40. [PMID: 31557279 DOI: 10.1093/ajcn/nqz240] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
68 Sævik F, Gilja OH, Nylund K. Gastrointestinal Ultrasound Can Predict Endoscopic Activity in Crohn's Disease. Ultraschall Med 2022;43:82-9. [PMID: 32330994 DOI: 10.1055/a-1149-9092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Sexton KA, Walker JR, Targownik LE, Graff LA, Haviva C, Beatie BE, Petty SK, Bernstein MT, Singh H, Miller N, Bernstein CN. The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application. Inflamm Bowel Dis 2019;25:1277-90. [PMID: 30918969 DOI: 10.1093/ibd/izz038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
70 Brennan Laing B, Cavadino A, Ellett S, Ferguson LR. Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations. Nutrients 2020;12:E1139. [PMID: 32325778 DOI: 10.3390/nu12041139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Park SM, Won DD, Lee BJ, Escobedo D, Esteva A, Aalipour A, Ge TJ, Kim JH, Suh S, Choi EH, Lozano AX, Yao C, Bodapati S, Achterberg FB, Kim J, Park H, Choi Y, Kim WJ, Yu JH, Bhatt AM, Lee JK, Spitler R, Wang SX, Gambhir SS. A mountable toilet system for personalized health monitoring via the analysis of excreta. Nat Biomed Eng 2020;4:624-35. [PMID: 32251391 DOI: 10.1038/s41551-020-0534-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 42] [Article Influence: 13.0] [Reference Citation Analysis]
72 Vagianos K, Shafer LA, Witges K, Targownik LE, Haviva C, Graff LA, Sexton KA, Lix LM, Sargent M, Bernstein CN. Association Between Change in Inflammatory Aspects of Diet and Change in IBD-related Inflammation and Symptoms Over 1 Year: The Manitoba Living With IBD Study. Inflamm Bowel Dis 2021;27:190-202. [PMID: 32206803 DOI: 10.1093/ibd/izaa052] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
73 Rottenstreich A, Mishael T, Granovsky SG, Koslowsky B, Schweistein H, Abitbol G, Goldin E, Shitrit AB. Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. Eur J Intern Med 2020;77:105-10. [PMID: 32197833 DOI: 10.1016/j.ejim.2020.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
74 Takenaka K, Kitazume Y, Fujii T, Tsuchiya K, Watanabe M, Ohtsuka K. Objective evaluation for treat to target in Crohn's disease. J Gastroenterol 2020;55:579-87. [PMID: 32130521 DOI: 10.1007/s00535-020-01678-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
75 Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, Danese S, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflamm Bowel Dis 2020;26:1562-71. [PMID: 32105310 DOI: 10.1093/ibd/izaa025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
76 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
77 D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. Review article: faecal calprotectin and histologic remission in ulcerative colitis.Aliment Pharmacol Ther. 2020;51:689-698. [PMID: 32048751 DOI: 10.1111/apt.15662] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
78 Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019;13:1012-1024. [PMID: 30726887 DOI: 10.1093/ecco-jcc/jjz023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
79 Deutschmann C, Sowa M, Murugaiyan J, Roesler U, Röber N, Conrad K, Laass MW, Bogdanos D, Sipeki N, Papp M, Rödiger S, Roggenbuck D, Schierack P. Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn's Disease. J Crohns Colitis 2019;13:894-904. [PMID: 30753386 DOI: 10.1093/ecco-jcc/jjz012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
80 Li BR, Sun T, Li J, Li M, Ning SB, Jin XW, Zhu M, Mao GP. Predictors for Small Bowel Stenosis in Balloon-Assisted Enteroscopy. Dig Dis Sci 2020;65:2630-6. [PMID: 31894488 DOI: 10.1007/s10620-019-05990-z] [Reference Citation Analysis]
81 Vernia F, Di Ruscio M, Stefanelli G, Viscido A, Frieri G, Latella G. Is fecal calprotectin an accurate marker in the management of Crohn's disease? J Gastroenterol Hepatol 2020;35:390-400. [PMID: 31795013 DOI: 10.1111/jgh.14950] [Cited by in Crossref: 15] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
82 Schoepfer A, Vavricka SR, Brüngger B, Blozik E, Bähler C. Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland. Eur J Gastroenterol Hepatol 2020;32:350-7. [PMID: 31834046 DOI: 10.1097/MEG.0000000000001616] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144-64. [PMID: 30137275 DOI: 10.1093/ecco-jcc/jjy113] [Cited by in Crossref: 313] [Cited by in F6Publishing: 440] [Article Influence: 104.3] [Reference Citation Analysis]
84 Chmiel C, Senn O, Hasler S, Rosemann T, Rogler G, Zahnd N, Tandjung R, Scherz N, Sulz MC, Vavricka S. Can the CalproQuest predict a positive Calprotectin test? A prospective diagnostic study. PLoS One 2019;14:e0224961. [PMID: 31751360 DOI: 10.1371/journal.pone.0224961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
85 Abedin N, Seemann T, Kleinfeld S, Ruehrup J, Röseler S, Trautwein C, Streetz K, Sellge G. Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease. J Clin Med 2019;8:E2025. [PMID: 31756948 DOI: 10.3390/jcm8122025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
86 Shentova R, Baycheva M, Hadjiiski P, Kofinova D, Yaneva P. Role of faecal calprotectin as a predictor of endoscopic activity in paediatric patients with ulcerative colitis. Gastroenterol Hepatol 2020;43:57-61. [PMID: 31733888 DOI: 10.1016/j.gastrohep.2019.08.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Bourgonje AR, von Martels JZH, Gabriëls RY, Blokzijl T, Buist-Homan M, Heegsma J, Jansen BH, van Dullemen HM, Festen EAM, Ter Steege RWF, Visschedijk MC, Weersma RK, de Vos P, Faber KN, Dijkstra G. A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. Front Med (Lausanne) 2019;6:251. [PMID: 31772929 DOI: 10.3389/fmed.2019.00251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
88 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol 2018;52:e53-62. [PMID: 28723856 DOI: 10.1097/MCG.0000000000000837] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
89 Af Björkesten CG, Jussila A, Kemppainen H, Hallinen T, Soini E, Mankinen P, Valgarðsson S, Veckman V, Nissinen R, Naessens D, Molander P. Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. Scand J Gastroenterol 2019;54:1226-32. [PMID: 31532265 DOI: 10.1080/00365521.2019.1667426] [Reference Citation Analysis]
90 Papoutsopoulou S, Burkitt MD, Bergey F, England H, Hough R, Schmidt L, Spiller DG, White MHR, Paszek P, Jackson DA, Martins Dos Santos VAP, Sellge G, Pritchard DM, Campbell BJ, Müller W, Probert CS. Macrophage-Specific NF-κB Activation Dynamics Can Segregate Inflammatory Bowel Disease Patients. Front Immunol 2019;10:2168. [PMID: 31572379 DOI: 10.3389/fimmu.2019.02168] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
91 Engström J, Lönnkvist M, Befrits R, Ljung T, Diaz-tartera H, Holst M, Hellström PM. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy. Scandinavian Journal of Gastroenterology 2019;54:1081-8. [DOI: 10.1080/00365521.2019.1660402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
92 Bourgonje AR, Gabriëls RY, de Borst MH, Bulthuis MLC, Faber KN, van Goor H, Dijkstra G. Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease. Antioxidants (Basel) 2019;8:E351. [PMID: 31480545 DOI: 10.3390/antiox8090351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
93 Khanna R, Narula N, Feagan BG. The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:1619-23. [PMID: 29846593 DOI: 10.1093/ibd/izy195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
94 Wright EK, Ding NS, Niewiadomski O. Management of inflammatory bowel disease. Med J Aust 2018;209:318-23. [PMID: 30257634 DOI: 10.5694/mja17.01001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
95 Kojecký V, Matouš J, Zádorová Z, Gřiva M, Kianička B, Uher M. Vitamin D supplementation dose needs to be higher in patients with inflammatory bowel disease: interventional study. Vnitř Lék 2019;65:470-4. [DOI: 10.36290/vnl.2019.083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. [PMID: 31236140 DOI: 10.1177/1756284819856865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
97 Amara J, Saliba Y, Hajal J, Smayra V, Bakhos JJ, Sayegh R, Fares N. Circadian Rhythm Disruption Aggravates DSS-Induced Colitis in Mice with Fecal Calprotectin as a Marker of Colitis Severity. Dig Dis Sci 2019;64:3122-33. [PMID: 31115725 DOI: 10.1007/s10620-019-05675-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
98 Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis 2018;24:277-85. [PMID: 29361090 DOI: 10.1093/ibd/izx018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
99 Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, Russell RK, Ruemmele FM, Escher JC, de Ridder L, Koletzko S, Martín-de-Carpi J, Hyams J, Walters T, Griffiths A, Turner D. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:133-140.e1. [PMID: 30981008 DOI: 10.1016/j.cgh.2019.04.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
100 Essmann J, Keil C, Unruh O, Otte A, Manns MP, Bachmann O. Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease. Eur J Gastroenterol Hepatol 2019;31:99-108. [PMID: 30212402 DOI: 10.1097/MEG.0000000000001262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
101 Lerchova T, Hradsky O, Copova I, Potuznikova K, Gonsorcikova L, Bronsky J. The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:75-81. [PMID: 30908389 DOI: 10.1097/MPG.0000000000002331] [Reference Citation Analysis]
102 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
103 Verdejo C, Hervías D, Roncero Ó, Arias Á, Bouhmidi A, Lorente R, Salueña I, Lucendo AJ. Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn's disease. Eur J Gastroenterol Hepatol 2018;30:1521-7. [PMID: 30303822 DOI: 10.1097/MEG.0000000000001284] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
104 Daniluk U, Daniluk J, Krasnodebska M, Lotowska JM, Sobaniec-Lotowska ME, Lebensztejn DM. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn's disease. Adv Med Sci 2019;64:9-14. [PMID: 30237086 DOI: 10.1016/j.advms.2018.08.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
105 Stevens TW, D'Haens GR, Duijvestein M, Bemelman WA, Buskens CJ, Gecse KB. Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas. United European Gastroenterol J 2019;7:496-506. [PMID: 31065367 DOI: 10.1177/2050640619834464] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
106 Ma C, Battat R, Khanna R, Parker CE, Feagan BG, Jairath V. What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity? Best Pract Res Clin Gastroenterol 2019;38-39:101602. [PMID: 31327404 DOI: 10.1016/j.bpg.2019.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
107 Grill M, Högenauer C, Blesl A, Haybaeck J, Golob-Schwarzl N, Ferreirós N, Thomas D, Gurke R, Trötzmüller M, Köfeler HC, Gallé B, Schicho R. Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. Sci Rep 2019;9:2358. [PMID: 30787385 DOI: 10.1038/s41598-019-38865-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
108 Minar P, Jackson K, Tsai YT, Sucharew H, Rosen MJ, Denson LA. Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease. Inflamm Bowel Dis 2017;24:198-208. [PMID: 29272485 DOI: 10.1093/ibd/izx022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
109 White JR, Jairath V, Moran GW. Evolution of treatment targets in Crohn's disease. Best Pract Res Clin Gastroenterol 2019;38-39:101599. [PMID: 31327410 DOI: 10.1016/j.bpg.2019.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. Clin Gastroenterol Hepatol. 2019;17:2269-2276. [PMID: 30772585 DOI: 10.1016/j.cgh.2019.02.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
111 Simon EG, Wardle R, Thi AA, Eldridge J, Samuel S, Moran GW. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? - a systematic review. Intest Res. 2019;. [PMID: 30704158 DOI: 10.5217/ir.2018.00114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
112 Monteiro S, Dias de Castro F, Leite S, Moreira MJ, Cotter J. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question. Scand J Gastroenterol 2019;54:49-54. [PMID: 30663515 DOI: 10.1080/00365521.2018.1549683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
113 Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Expert Review of Gastroenterology & Hepatology 2019;13:319-30. [DOI: 10.1080/17474124.2019.1563481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
114 Jones GR, Fascì-spurio F, Kennedy NA, Plevris N, Jenkinson P, Lyons M, Wong L, Maclean P, Glancy S, Lees CW. Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn’s Disease: Correlations Between Disease Activity and Long-Term Follow-Up. Journal of Crohn's and Colitis 2019;13:442-50. [DOI: 10.1093/ecco-jcc/jjy187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
115 Witges K, Targownik LE, Haviva C, Walker JR, Graff LA, Sexton KA, Lix L, Sargent M, Vagianos K, Bernstein CN. Living With Inflammatory Bowel Disease: Protocol for a Longitudinal Study of Factors Associated With Symptom Exacerbations. JMIR Res Protoc 2018;7:e11317. [PMID: 30425031 DOI: 10.2196/11317] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
116 Chmiel C, Vavricka SR, Hasler S, Rogler G, Zahnd N, Schiesser S, Tandjung R, Scherz N, Rosemann T, Senn O. Feasibility of an 8-item questionnaire for early diagnosis of inflammatory bowel disease in primary care. J Eval Clin Pract 2019;25:155-62. [PMID: 30324695 DOI: 10.1111/jep.13046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
117 Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2018;41:514-29. [DOI: 10.1016/j.gastre.2018.05.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2018;41:514-29. [DOI: 10.1016/j.gastrohep.2018.05.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
119 Bamidele AO, Svingen PA, Sagstetter MR, Sarmento OF, Gonzalez M, Braga Neto MB, Kugathasan S, Lomberk G, Urrutia RA, Faubion WA Jr. Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation. Cell Mol Gastroenterol Hepatol 2019;7:55-71. [PMID: 30510991 DOI: 10.1016/j.jcmgh.2018.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
120 Zhang H, Zeng Z, Mukherjee A, Shen B. Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018;18:867-886. [PMID: 30152711 DOI: 10.1080/14737159.2018.1516549] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
121 Iwamoto F, Matsuoka K, Motobayashi M, Takenaka K, Kuno T, Tanaka K, Tsukui Y, Kobayashi S, Yoshida T, Fujii T, Saito E, Yamaguchi T, Nagahori M, Sato T, Ohtsuka K, Enomoto N, Watanabe M. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol 2018;33:1984-9. [PMID: 29889986 DOI: 10.1111/jgh.14310] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
122 Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1425-1433. [PMID: 28570431 DOI: 10.1097/mib.0000000000001140] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 23.0] [Reference Citation Analysis]
123 Arnott I, Rogler G, Halfvarson J. The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives. Inflamm Intest Dis 2018;2:189-99. [PMID: 30221146 DOI: 10.1159/000490053] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
124 Reenaers C, Bossuyt P, Hindryckx P, Vanpoucke H, Cremer A, Baert F. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J 2018;6:1117-25. [PMID: 30288273 DOI: 10.1177/2050640618784046] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
125 Kawashima K, Ishihara S, Yuki T, Fukuba N, Sonoyama H, Kazumori H, Yamashita N, Tada Y, Kusunoki R, Oka A, Oshima N, Mishima Y, Moriyama I, Kinoshita Y. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy. Inflamm Bowel Dis 2017;23:2027-34. [PMID: 28817462 DOI: 10.1097/MIB.0000000000001202] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
126 Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. Inflamm Bowel Dis 2017;23:2048-53. [PMID: 28945636 DOI: 10.1097/MIB.0000000000001223] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
127 Vetter M, Neurath M. Treatment Perspectives in Crohn’s Disease. Digestion 2018;98:135-42. [DOI: 10.1159/000488449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
128 Vavricka SR, Heinrich H, Buetikofer S, Breitenmoser F, Burri E, Schneider-Yin X, Barman-Aksoezen J, Biedermann L, Scharl M, Zeitz J, Rogler G, Misselwitz B, Sauter M. The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. United European Gastroenterol J 2018;6:1007-14. [PMID: 30228888 DOI: 10.1177/2050640618774416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
129 Hoekman DR, Zeevenhooven J, D'Haens GR, Benninga MA. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission. Eur J Gastroenterol Hepatol. 2017;29:1086-1090. [PMID: 28639969 DOI: 10.1097/meg.0000000000000921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
130 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 390] [Cited by in F6Publishing: 451] [Article Influence: 97.5] [Reference Citation Analysis]
131 Gray MA, Chao CY, Staudacher HM, Kolosky NA, Talley NJ, Holtmann G. Anti-TNFα therapy in IBD alters brain activity reflecting visceral sensory function and cognitive-affective biases. PLoS One 2018;13:e0193542. [PMID: 29518097 DOI: 10.1371/journal.pone.0193542] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
132 Weinstein-Nakar I, Focht G, Church P, Walters TD, Abitbol G, Anupindi S, Berteloot L, Hulst JM, Ruemmele F, Lemberg DA, Leach ST, Cytter R, Greer ML, Griffiths AM, Turner D; ImageKids study group. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease. Clin Gastroenterol Hepatol 2018; 16: 1089-1097. e4. [PMID: 29501599 DOI: 10.1016/j.cgh.2018.01.024] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 14.8] [Reference Citation Analysis]
133 Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Gradel KO, Friedman S, Nørgård BM. Fecal Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:839-48. [DOI: 10.1093/ibd/izx055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
134 Hassan EA, Ramadan HK, Ismael AA, Mohamed KF, El-Attar MM, Alhelali I. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. Saudi J Gastroenterol 2017;23:238-45. [PMID: 28721978 DOI: 10.4103/sjg.SJG_599_16] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
135 Lopes S, Andrade P, Afonso J, Rodrigues-Pinto E, Dias CC, Macedo G, Magro F. Correlation Between Calprotectin and Modified Rutgeerts Score. Inflamm Bowel Dis. 2016;22:2173-2181. [PMID: 27482974 DOI: 10.1097/mib.0000000000000850] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
136 Baillet P, Cadiot G, Goutte M, Goutorbe F, Brixi H, Hoeffel C, Allimant C, Reymond M, Obritin-Guilhen H, Magnin B, Bommelaer G, Pereira B, Hordonneau C, Buisson A. Faecal calprotectin and magnetic resonance imaging in detecting Crohn’s disease endoscopic postoperative recurrence. World J Gastroenterol 2018; 24(5): 641-650 [PMID: 29434453 DOI: 10.3748/wjg.v24.i5.641] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
137 Smids C, Horjus Talabur Horje CS, Nierkens S, Drylewicz J, Groenen MJM, Wahab PJ, van Lochem EG. Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course. J Crohns Colitis 2017;11:1090-100. [PMID: 28369318 DOI: 10.1093/ecco-jcc/jjx049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
138 Garcia-Planella E, Mañosa M, Cabré E, Marín L, Gordillo J, Zabana Y, Boix J, Sáinz S, Domènech E. Fecal Calprotectin Levels Are Closely Correlated with the Absence of Relevant Mucosal Lesions in Postoperative Crohn's Disease. Inflamm Bowel Dis 2016;22:2879-85. [PMID: 27824646 DOI: 10.1097/MIB.0000000000000960] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
139 Bhattacharya A, Rao BB, Koutroubakis IE, Click B, Vargas EJ, Regueiro M, Schwartz M, Swoger JM, Babichenko D, Hartmann D, Rivers CR, Barrie A, Hashash JG, Dunn MA, Binion DG. Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation. Inflamm Bowel Dis. 2016;22:2665-2671. [PMID: 27753691 DOI: 10.1097/mib.0000000000000935] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
140 Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ, Chung WC, Paik CN. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J Intern Med. 2019;34:72-80. [PMID: 29347813 DOI: 10.3904/kjim.2016.324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
141 Derwa Y, Williams CJM, Sood R, Mumtaz S, Bholah MH, Selinger CP, Hamlin PJ, Ford AC, Gracie DJ. Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. Therap Adv Gastroenterol. 2018;11:1756283X17744739. [PMID: 29383026 DOI: 10.1177/1756283x17744739] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
142 Jusué V, Chaparro M, Gisbert JP. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Dig Liver Dis 2018;50:353-9. [PMID: 29396129 DOI: 10.1016/j.dld.2017.12.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
143 Rosenfeld G, Brown J, Vos PM, Leipsic J, Enns R, Bressler B. Prospective Comparison of Standard- Versus Low-Radiation-Dose CT Enterography for the Quantitative Assessment of Crohn Disease. AJR Am J Roentgenol 2018;210:W54-62. [PMID: 29261354 DOI: 10.2214/AJR.17.18296] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
144 Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China. World J Gastroenterol 2017; 23(46): 8235-8247 [PMID: 29290660 DOI: 10.3748/wjg.v23.i46.8235] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
145 Horie K, Mikami T, Yoshida T, Sato Y, Okayasu I. Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry. Oncol Lett 2018;15:2364-72. [PMID: 29434945 DOI: 10.3892/ol.2017.7549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
146 Okazaki N, Inokuchi T, Hiraoka S, Ohmori M, Takashima S, Takei D, Sugihara Y, Takahara M, Harada K, Kawano S, Okada H, Kato J. Findings of Retrograde Contrast Study Through Double-balloon Enteroscopy Predict the Risk of Bowel Resections in Patients with Crohnʼs Disease with Small Bowel Stenosis: . Inflammatory Bowel Diseases 2017;23:2097-103. [DOI: 10.1097/mib.0000000000001175] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
147 Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396 [PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 36] [Article Influence: 9.2] [Reference Citation Analysis]
148 Epelboym Y, Shyn PB, Chick JFB, Hamilton MJ, O'connor SD, Silverman SG, Kim CK. Crohn Disease: FDG PET/CT Before and After Initial Dose of Anti–Tumor Necrosis Factor Therapy to Predict Long-term Response. Clin Nucl Med 2017;42:837-41. [DOI: 10.1097/rlu.0000000000001844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
149 Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. [PMID: 29027257 DOI: 10.1111/apt.14368] [Cited by in Crossref: 167] [Cited by in F6Publishing: 153] [Article Influence: 33.4] [Reference Citation Analysis]
150 Puolanne A, Kolho K, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3123-30. [DOI: 10.1007/s10620-017-4770-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
151 Aggarwal V, Day AS, Connor S, Leach ST, Brown G, Singh R, Friedman A, Zekry A, Craig PI. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse. Gastrointest Endosc. 2017;86:1070-1078. [PMID: 28947363 DOI: 10.1016/j.gie.2017.09.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
152 Cummins G, Yung DE, Cox BF, Koulaouzidis A, Desmulliez MPY, Cochran S. Luminally expressed gastrointestinal biomarkers. Expert Review of Gastroenterology & Hepatology 2017;11:1119-34. [DOI: 10.1080/17474124.2017.1373017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
153 Thorsvik S, Damås JK, Granlund AV, Flo TH, Bergh K, Østvik AE, Sandvik AK. Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease. J Gastroenterol Hepatol 2017;32:128-35. [PMID: 27640344 DOI: 10.1111/jgh.13598] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
154 Whitehead SJ, Ford C, Gama RM, Ali A, Mckaig B, Waldron JL, Steed H, Brookes MJ. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. J Clin Pathol 2017;70:1049-56. [DOI: 10.1136/jclinpath-2017-204340] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
155 Yamamoto T, Shimoyama T. Monitoring and detection of disease recurrence after resection for Crohn’s disease: the role of non-invasive fecal biomarkers. Expert Review of Gastroenterology & Hepatology 2017;11:899-909. [DOI: 10.1080/17474124.2017.1356226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
156 Zhang J, Guo Z, Yang W, Zhu Z, Kong W, Zheng S, Jiang L, Fei X, Chen Y, Liu J. D-Dimer levels are correlated with disease activity in Crohn's patients. Oncotarget 2017;8:63971-7. [PMID: 28969045 DOI: 10.18632/oncotarget.19250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
157 Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal biomarkers for screening small bowel inflammation in patients with Crohn's disease: a prospective study. Therap Adv Gastroenterol 2017;10:577-87. [PMID: 28835772 DOI: 10.1177/1756283X17717683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
158 Ye L, Chen BQ, Wang SD, Shi H, Yang Z, Wang FY. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study. Scand J Gastroenterol 2017;52:1113-9. [PMID: 28675068 DOI: 10.1080/00365521.2017.1346704] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
159 Julsgaard M, Hvas CL, Gearry RB, Vestergaard T, Fallingborg J, Svenningsen L, Kjeldsen J, Sparrow MP, Wildt S, Kelsen J, Bell SJ. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017;23:1240-6. [DOI: 10.1097/mib.0000000000001136] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
160 Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohnʼs Disease. Inflammatory Bowel Diseases 2017;23:1047-56. [DOI: 10.1097/mib.0000000000001100] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
161 Kopylov U, Yung DE, Engel T, Avni T, Battat R, Ben-Horin S, Plevris JN, Eliakim R, Koulaouzidis A. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016;28:1137-1144. [PMID: 27415156 DOI: 10.1097/meg.0000000000000692] [Cited by in Crossref: 51] [Cited by in F6Publishing: 64] [Article Influence: 10.2] [Reference Citation Analysis]
162 Oh K, Oh EH, Baek S, Song EM, Kim GU, Seo M, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease. PLoS One. 2017;12:e0179266. [PMID: 28622356 DOI: 10.1371/journal.pone.0179266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
163 Chang J, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. Gastroenterology 2017; 153: 723-731. e1. [PMID: 28601482 DOI: 10.1053/j.gastro.2017.05.056] [Cited by in Crossref: 92] [Cited by in F6Publishing: 126] [Article Influence: 18.4] [Reference Citation Analysis]
164 Fu Y, Wang L, Xie C, Zou K, Tu L, Yan W, Hou X. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017;7:2669. [PMID: 28572616 DOI: 10.1038/s41598-017-02835-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
165 Pous-serrano S, Frasson M, Cerrillo E, Beltrán B, Iborra M, Hervás D, García-granero E, Nos P. Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease. Journal of Surgical Research 2017;213:290-7. [DOI: 10.1016/j.jss.2017.02.064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
166 Ye L, Cheng W, Chen BQ, Lan X, Wang SD, Wu XC, Huang W, Wang FY. Levels of Faecal Calprotectin and Magnetic Resonance Enterocolonography Correlate with Severity of Small Bowel Crohn's Disease: A Retrospective Cohort Study. Sci Rep 2017;7:1970. [PMID: 28512287 DOI: 10.1038/s41598-017-02111-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
167 Koutroumpakis E, Katsanos KH. Implementation of the simple endoscopic activity score in crohn's disease. Saudi J Gastroenterol 2016;22:183-91. [PMID: 27184635 DOI: 10.4103/1319-3767.182455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
168 Lee J. [Fecal Calprotectin in Inflammatory Bowel Disease]. Korean J Gastroenterol 2016;67:233-7. [PMID: 27206433 DOI: 10.4166/kjg.2016.67.5.233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
169 Rogler G. Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2017;2:521-30. [PMID: 28606878 DOI: 10.1016/S2468-1253(17)30031-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 6.2] [Reference Citation Analysis]
170 Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291-1302. [PMID: 28326566 DOI: 10.1111/apt.14030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 158] [Article Influence: 34.4] [Reference Citation Analysis]
171 Manceau H, Chicha-Cattoir V, Puy H, Peoc'h K. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55:474-483. [PMID: 27658156 DOI: 10.1515/cclm-2016-0522] [Cited by in Crossref: 39] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
172 Kim DH, Park Y, Kim B, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behçet's disease: Fecal calprotectin in intestinal BD. Journal of Gastroenterology and Hepatology 2017;32:595-601. [DOI: 10.1111/jgh.13530] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
173 Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, Reynolds J, Gibson PR, Sparrow MP. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther 2017;45:1135-45. [PMID: 28239869 DOI: 10.1111/apt.13992] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
174 Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol 2017;11:317-28. [PMID: 28276813 DOI: 10.1080/17474124.2017.1292128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
175 Lee HW, Chung SH, Moon CM, Che X, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease. Medicine (Baltimore) 2016;95:e3772. [PMID: 27281077 DOI: 10.1097/MD.0000000000003772] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
176 Kochhar G, Lashner B. Utility of Biomarkers in the Management of Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2017;15:105-15. [PMID: 28138859 DOI: 10.1007/s11938-017-0129-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
177 El-Matary W, Abej E, Deora V, Singh H, Bernstein CN. Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease. Front Pediatr 2017;5:7. [PMID: 28180127 DOI: 10.3389/fped.2017.00007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
178 Jensen MD, Brodersen JB, Kjeldsen J. Capsule endoscopy for the diagnosis and follow up of Crohn's disease: a comprehensive review of current status. Ann Gastroenterol. 2017;30:168-178. [PMID: 28243037 DOI: 10.20524/aog.2016.0119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
179 Bodelier AG, Jonkers D, van den Heuvel T, de Boer E, Hameeteman W, Masclee AA, Pierik MJ. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score. Dig Dis Sci. 2017;62:465-472. [PMID: 27933473 DOI: 10.1007/s10620-016-4397-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
180 Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT, Nimmo ER, Visconti MR, Drummond H, Ho G, Pattenden RJ, Wilson DC, Satsangi J. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. American Journal of Gastroenterology 2016;111:1796-805. [DOI: 10.1038/ajg.2016.342] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
181 Kucharzik T, Wittig BM, Helwig U, Börner N, Rössler A, Rath S, Maaser C; TRUST study group. Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. Clin Gastroenterol Hepatol 2017;15:535-542.e2. [PMID: 27856365 DOI: 10.1016/j.cgh.2016.10.040] [Cited by in Crossref: 107] [Cited by in F6Publishing: 85] [Article Influence: 17.8] [Reference Citation Analysis]
182 Menys A, Makanyanga J, Plumb A, Bhatnagar G, Atkinson D, Emmanuel A, Taylor SA. Aberrant Motility in Unaffected Small Bowel is Linked to Inflammatory Burden and Patient Symptoms in Crohn's Disease. Inflamm Bowel Dis. 2016;22:424-432. [PMID: 26509756 DOI: 10.1097/mib.0000000000000601] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
183 Jang HW, Kim HS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease. Intest Res 2016;14:305-13. [PMID: 27799881 DOI: 10.5217/ir.2016.14.4.305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
184 Abej E, El-Matary W, Singh H, Bernstein CN. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2016;2016:2483261. [PMID: 27774443 DOI: 10.1155/2016/2483261] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
185 Rosenfeld G, Greenup AJ, Round A, Takach O, Halparin L, Saadeddin A, Ho JK, Lee T, Enns R, Bressler B. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World J Gastroenterol 2016; 22(36): 8211-8218 [PMID: 27688663 DOI: 10.3748/wjg.v22.i36.8211] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
186 Gauss A, Geib T, Hinz U, Schaefert R, Zwickel P, Zawierucha A, Stremmel W, Klute L. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. Medicine (Baltimore). 2016;95:e3477. [PMID: 27100452 DOI: 10.1097/md.0000000000003477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
187 Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. Eur J Clin Invest 2016;46:825-32. [PMID: 27438629 DOI: 10.1111/eci.12660] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
188 Hoekman DR, Diederen K, Koot BG, Tabbers MM, Kindermann A, Benninga MA. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Eur J Pediatr 2016;175:1335-42. [PMID: 27573259 DOI: 10.1007/s00431-016-2762-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
189 Díaz-Jiménez D, De la Fuente M, Dubois-Camacho K, Landskron G, Fuentes J, Pérez T, González MJ, Simian D, Hermoso MA, Quera R. Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol 2016;16:103. [PMID: 27565556 DOI: 10.1186/s12876-016-0520-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
190 Iborra M, Beltrán B, Nos P. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2016;26:641-56. [PMID: 27633593 DOI: 10.1016/j.giec.2016.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
191 Khanna R, Nelson SA, Feagan BG, D'Haens G, Sandborn WJ, Zou GY, MacDonald JK, Parker CE, Jairath V, Levesque BG. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev 2016;:CD010642. [PMID: 27501379 DOI: 10.1002/14651858.CD010642.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
192 Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvenstein M, Rimola J, Panes J, D’haens G, Sandborn WJ, Feagan BG. Evolving Concepts in Phases I and II Drug Development for Crohn’s Disease. ECCOJC 2017;11:246-55. [DOI: 10.1093/ecco-jcc/jjw137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
193 Subramanian S, Asher R, Weston W, Rimmer M, Mcconville A, Malin A, Jackson R, Collins P, Probert C, Dibb M, Rhodes JM. Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use: . Inflammatory Bowel Diseases 2016;22:1902-7. [DOI: 10.1097/mib.0000000000000803] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
194 Scott FI, Lichtenstein GR. Approach to the Patient with Mild Crohn’s Disease: a 2016 Update. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-016-0523-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
195 Jiang J, Click B, Anderson AM, Koutroubakis IE, Rivers CR, Hashash JG, Dunn MA, Schwartz M, Swoger J, Barrie A, Regueiro M, Chang CC, Binion DG. Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. Clin Transl Gastroenterol 2016;7:e181. [PMID: 27415619 DOI: 10.1038/ctg.2016.39] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
196 Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysk C, Halfvarson J. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016;44:495-504. [PMID: 27402063 DOI: 10.1111/apt.13731] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
197 Bodelier AG, Pierik MJ, Lenaerts K, de Boer E, Olde Damink SW, Hameeteman WM, Masclee AA, Jonkers DM. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients: . European Journal of Gastroenterology & Hepatology 2016;28:807-13. [DOI: 10.1097/meg.0000000000000616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
198 Zhuge Y, Huang QP, Li Q, Wang JS. Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis. Euroasian J Hepatogastroenterol 2016;6:116-24. [PMID: 29201742 DOI: 10.5005/jp-journals-10018-1182] [Reference Citation Analysis]
199 Pagnini C, Menasci F, Desideri F, Corleto VD, Delle Fave G, Di Giulio E. Endoscopic scores for inflammatory bowel disease in the era of ‘mucosal healing’: Old problem, new perspectives. Digestive and Liver Disease 2016;48:703-8. [DOI: 10.1016/j.dld.2016.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
200 Click B, Vargas EJ, Anderson AM, Proksell S, Koutroubakis IE, Ramos Rivers C, Hashash JG, Regueiro M, Watson A, Dunn MA, Schwartz M, Swoger J, Baidoo L, Barrie A 3rd, Binion DG. Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization. Inflamm Bowel Dis 2015;21:2254-61. [PMID: 26197446 DOI: 10.1097/MIB.0000000000000516] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
201 Inokuchi T, Kato J, Hiraoka S, Takashima S, Nakarai A, Takei D, Sugihara Y, Takahara M, Kawano S, Harada K, Okada H. Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohnʼs Disease: . Inflammatory Bowel Diseases 2016;22:1078-85. [DOI: 10.1097/mib.0000000000000728] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
202 Niewiadomski O, Studd C, Hair C, Wilson J, Ding NS, Heerasing N, Ting A, McNeill J, Knight R, Santamaria J. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity. J Gastroenterol Hepatol. 2015;30:1346-1353. [PMID: 25867770 DOI: 10.1111/jgh.12967] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
203 Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC. Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. Am J Gastroenterol. 2016;111:541-551. [PMID: 27002800 DOI: 10.1038/ajg.2016.59] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 12.0] [Reference Citation Analysis]
204 Rogler G, Biedermann L. Clinical Utility of Biomarkers in IBD. Curr Gastroenterol Rep. 2015;17:26. [PMID: 26122247 DOI: 10.1007/s11894-015-0449-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
205 Grover Z, Burgess C, Muir R, Reilly C, Lewindon PJ. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn’s disease. ECCOJC 2016;10:1159-64. [DOI: 10.1093/ecco-jcc/jjw075] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
206 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43:1069-1079. [PMID: 26953251 DOI: 10.1111/apt.13585] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
207 Alibrahim B, Aljasser MI, Salh B. Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review. Can J Gastroenterol Hepatol 2015;29:157-63. [PMID: 25855880 DOI: 10.1155/2015/950286] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
208 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 220] [Cited by in F6Publishing: 198] [Article Influence: 36.7] [Reference Citation Analysis]
209 Ikhtaire S, Shajib MS, Reinisch W, Khan WI. Fecal calprotectin: Its scope and utility in the management of inflammatory bowel disease. J Gastroenterol. 2016;51:434-446. [PMID: 26897740 DOI: 10.1007/s00535-016-1182-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
210 Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. ECCOJC 2016;10:989-97. [DOI: 10.1093/ecco-jcc/jjw053] [Cited by in Crossref: 128] [Cited by in F6Publishing: 149] [Article Influence: 21.3] [Reference Citation Analysis]
211 Zubin G, Peter L. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin. Inflamm Bowel Dis 2015;21:1386-91. [PMID: 25851564 DOI: 10.1097/MIB.0000000000000388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
212 Teruel C, Garrido E, Mesonero F. Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther 2016; 7(1): 78-90 [PMID: 26855814 DOI: 10.4292/wjgpt.v7.i1.78] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
213 Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21-29. [PMID: 26869808 DOI: 10.2147/ceg.s51902] [Cited by in Crossref: 34] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
214 Kato J, Hiraoka S, Nakarai A, Takashima S, Inokuchi T, Ichinose M. Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res. 2016;14:5-14. [PMID: 26884729 DOI: 10.5217/ir.2016.14.1.5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
215 Klingberg E, Oleröd G, Hammarsten O, Forsblad-d'Elia H. The vitamin D status in ankylosing spondylitis in relation to intestinal inflammation, disease activity, and bone health: a cross-sectional study. Osteoporos Int 2016;27:2027-33. [PMID: 26809190 DOI: 10.1007/s00198-016-3489-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
216 Morimoto K, Watanabe K, Noguchi A, Miyazaki T, Nagami Y, Sugimori S, Kamata N, Sogawa M, Tanigawa T, Yamagami H, Shiba M, Tominaga K, Watanabe T, Fujiwara Y, Arakawa T. Clinical impact of ultrathin colonoscopy for Crohn's disease patients with strictures. J Gastroenterol Hepatol 2015;30 Suppl 1:66-70. [PMID: 25827807 DOI: 10.1111/jgh.12739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
217 Lin WC, Wong JM, Tung CC, Lin CP, Chou JW, Wang HY, Shieh MJ, Chang CH, Liu HH, Wei SC, Taiwan Society of Inflammatory Bowel Disease Multicenter Study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol 2015; 21(48): 13566-13573 [PMID: 26730169 DOI: 10.3748/wjg.v21.i48.13566] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
218 Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, Gearry RB. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21:824-831. [PMID: 25738372 DOI: 10.1097/mib.0000000000000341] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 13.3] [Reference Citation Analysis]
219 Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11246-11259 [PMID: 26523100 DOI: 10.3748/wjg.v21.i40.11246] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 74] [Article Influence: 13.1] [Reference Citation Analysis]
220 Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480 [PMID: 26523111 DOI: 10.3748/wjg.v21.i40.11469] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
221 Bewtra M, Fairchild AO, Gilroy E, Leiman DA, Kerner C, Johnson FR, Lewis JD. Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse. Am J Gastroenterol 2015;110:1675-81. [PMID: 26482859 DOI: 10.1038/ajg.2015.321] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
222 Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74-80. [PMID: 25523558 DOI: 10.3109/00365521.2014.987809] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 9.4] [Reference Citation Analysis]
223 Morise K, Ando T, Watanabe O, Nakamura M, Miyahara R, Maeda O, Ishiguro K, Hirooka Y, Goto H. Clinical utility of a new endoscopic scoring system for Crohn’s disease. World J Gastroenterol 2015; 21(34): 9974-9981 [PMID: 26379402 DOI: 10.3748/wjg.v21.i34.9974] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
224 Yang DH, Yang SK, Park SH, Lee HS, Boo SJ, Park JH, Na SY, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ. Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease. Gut Liver 2015;9:80-6. [PMID: 25170056 DOI: 10.5009/gnl13424] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
225 Goutorbe F, Goutte M, Minet-Quinard R, Boucher AL, Pereira B, Bommelaer G, Buisson A. Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. J Crohns Colitis. 2015;9:1113-1119. [PMID: 26351383 DOI: 10.1093/ecco-jcc/jjv150] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
226 Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825-34. [PMID: 26342731 DOI: 10.1016/S0140-6736(15)00068-9] [Cited by in F6Publishing: 83] [Reference Citation Analysis]
227 Schoepfer A, Reinisch W. Serial Fecal Calprotectin and Lactoferrin Measurements for Early Diagnosis of Pouchitis After Proctocolectomy for Ulcerative Colitis: Is Pouchoscopy No Longer Needed? Am J Gastroenterol. 2015;110:888-890. [PMID: 26052770 DOI: 10.1038/ajg.2015.170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
228 Lee D, Baldassano RN, Otley AR, Albenberg L, Griffiths AM, Compher C, Chen EZ, Li H, Gilroy E, Nessel L, Grant A, Chehoud C, Bushman FD, Wu GD, Lewis JD. Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohnʼs Disease: . Inflammatory Bowel Diseases 2015;21:1786-93. [DOI: 10.1097/mib.0000000000000426] [Cited by in Crossref: 98] [Cited by in F6Publishing: 79] [Article Influence: 14.0] [Reference Citation Analysis]
229 Bodelier AGL, Smolinska A, Baranska A, Dallinga JW, Mujagic Z, Vanhees K, van den Heuvel T, Masclee AAM, Jonkers D, Pierik MJ, van Schooten FJ. Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohnʼs Disease: A Metabolomic Approach. Inflammatory Bowel Diseases 2015;21:1776-85. [DOI: 10.1097/mib.0000000000000436] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
230 Sachar DB; Biomarkers Task Force of the IOIBD. Role of biomarkers in the study and management of inflammatory bowel disease: a "nonsystematic" review. Inflamm Bowel Dis 2014;20:2511-8. [PMID: 25222663 DOI: 10.1097/MIB.0000000000000135] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
231 Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology. 2015;149:1275-1285.e2. [PMID: 26166315 DOI: 10.1053/j.gastro.2015.07.003] [Cited by in Crossref: 150] [Cited by in F6Publishing: 172] [Article Influence: 21.4] [Reference Citation Analysis]
232 Bressler B, Panaccione R, Fedorak RN, Seidman EG. Clinicians’ guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol. 2015;29:369-372. [PMID: 26125109 DOI: 10.1155/2015/852723] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
233 Targownik LE, Sexton KA, Bernstein MT, Beatie B, Sargent M, Walker JR, Graff LA. The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. Am J Gastroenterol. 2015;110:1001-12; quiz 1013. [PMID: 26077178 DOI: 10.1038/ajg.2015.147] [Cited by in Crossref: 82] [Cited by in F6Publishing: 89] [Article Influence: 11.7] [Reference Citation Analysis]
234 Grover Z, Lewindon P. Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn's Disease Treated Early with Thiopurines. Dig Dis Sci 2015;60:3069-74. [PMID: 26038093 DOI: 10.1007/s10620-015-3722-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
235 Torki M, Gholamrezaei A, Mirbagher L, Danesh M, Kheiri S, Emami MH. Vitamin D Deficiency Associated with Disease Activity in Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2015;60:3085-91. [PMID: 26031421 DOI: 10.1007/s10620-015-3727-4] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
236 Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm Bowel Dis. 2014;20:1668-1677. [PMID: 24918319 DOI: 10.1097/mib.0000000000000087] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
237 Guo Y, Zhou G, He C, Yang W, He Z, Liu Z. Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease. Mediators Inflamm 2015;2015:843089. [PMID: 26106258 DOI: 10.1155/2015/843089] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
238 Jiang W, Li X. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Mol Diagn Ther 2015;19:141-58. [DOI: 10.1007/s40291-015-0142-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
239 Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015;110:802-19; quiz 820. [PMID: 25964225 DOI: 10.1038/ajg.2015.120] [Cited by in Crossref: 275] [Cited by in F6Publishing: 294] [Article Influence: 39.3] [Reference Citation Analysis]
240 Stawczyk-Eder K, Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Klimczak K, Szymczak A, Szachta P, Katulska K, Linke K. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study. Arch Med Sci. 2015;11:353-361. [PMID: 25995752 DOI: 10.5114/aoms.2014.43672] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
241 Inoue K, Aomatsu T, Yoden A, Okuhira T, Kaji E, Tamai H. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases. J Gastroenterol Hepatol. 2014;29:1406-1412. [PMID: 24635100 DOI: 10.1111/jgh.12578] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
242 Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ, Deng FH, Nie B, Jiang B. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407-1415. [PMID: 24983982 DOI: 10.1097/mib.0000000000000057] [Cited by in Crossref: 197] [Cited by in F6Publishing: 186] [Article Influence: 28.1] [Reference Citation Analysis]
243 Schoepfer AM, Lewis JD. Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn’s disease: is colonoscopic surveillance no longer needed? Gastroenterology. 2015;148:889-892. [PMID: 25805423 DOI: 10.1053/j.gastro.2015.03.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
244 Boschetti G, Laidet M, Moussata D, Stefanescu C, Roblin X, Phelip G, Cotte E, Passot G, Francois Y, Drai J. Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn’s Disease. Am J Gastroenterol. 2015;110:865-872. [PMID: 25781366 DOI: 10.1038/ajg.2015.30] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 11.3] [Reference Citation Analysis]
245 Raftery T, Merrick M, Healy M, Mahmud N, O'Morain C, Smith S, McNamara D, O'Sullivan M. Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn's Disease in Clinical Remission. Dig Dis Sci 2015;60:2427-35. [PMID: 25757449 DOI: 10.1007/s10620-015-3620-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
246 Hasler S, Zahnd N, Müller S, Vavricka S, Rogler G, Tandjung R, Rosemann T. VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study. BMJ Open. 2015;5:e007306. [PMID: 25757949 DOI: 10.1136/bmjopen-2014-007306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
247 Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444-454. [PMID: 25732419 DOI: 10.1038/ajg.2015.6] [Cited by in Crossref: 170] [Cited by in F6Publishing: 169] [Article Influence: 24.3] [Reference Citation Analysis]
248 Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742-756. [PMID: 24562174 DOI: 10.1097/01.mib.0000442681.85545.31] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 15.3] [Reference Citation Analysis]
249 Sajjadi M, Gholamrezaei A, Daryani NE. No association between serum adenosine deaminase activity and disease activity in Crohn's disease. Dig Dis Sci. 2015;60:1755-1760. [PMID: 25652144 DOI: 10.1007/s10620-014-3510-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
250 Gecse KB, Brandse JF, van Wilpe S, Löwenberg M, Ponsioen C, van den Brink G, D’Haens G. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand J Gastroenterol. 2015;50:841-847. [PMID: 25636819 DOI: 10.3109/00365521.2015.1008035] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
251 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Leach S, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Day AS, Desmond PV, Gearry RB. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015;148:938-947.e1. [PMID: 25620670 DOI: 10.1053/j.gastro.2015.01.026] [Cited by in Crossref: 170] [Cited by in F6Publishing: 171] [Article Influence: 24.3] [Reference Citation Analysis]
252 Farkas K, Saródi Z, Bálint A, Földesi I, Tiszlavicz L, Szűcs M, Nyári T, Tajti J, Nagy F, Szepes Z, Bor R, Annaházi A, Róka R, Molnár T. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. J Crohns Colitis 2015;9:231-7. [PMID: 25585596 DOI: 10.1093/ecco-jcc/jjv005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
253 Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis. 2014;20:307-314. [PMID: 24374878 DOI: 10.1097/01.mib.0000438428.30800.a6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
254 Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8:23-36. [PMID: 25553077 DOI: 10.1177/1756283x14553384] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 13.6] [Reference Citation Analysis]
255 Minar P, Haberman Y, Jurickova I, Wen T, Rothenberg ME, Kim MO, Saeed SA, Baldassano RN, Stephens M, Markowitz J, Rosh J, Crandall WV, Heyman MB, Mack DR, Griffiths AM, Baker SS, Hyams JS, Kugathasan S, Denson LA. Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1037-48. [PMID: 24788216 DOI: 10.1097/MIB.0000000000000049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
256 Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Fecal calprotectin testing can identify ineffective colorectal cancer surveillance procedures in patients with longstanding colitis. Inflamm Bowel Dis. 2014;20:1079-1084. [PMID: 24788218 DOI: 10.1097/MIB.0000000000000054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
257 Meng LL, Wu ZJ. Clinical utility of fecal neutrophil-derived biomarkers in evaluating activity of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2014; 22(35): 5473-5479 [DOI: 10.11569/wcjd.v22.i35.5473] [Reference Citation Analysis]
258 Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
259 Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
260 Malgras B, Pautrat K, Dray X, Pasquier P, Valleur P, Pocard M, Soyer P. Multidisciplinary Management of Gastrointestinal Fibrotic Stenosis in Crohn’s Disease. Dig Dis Sci 2015;60:1152-68. [DOI: 10.1007/s10620-014-3421-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
261 Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Digestive and Liver Disease 2014;46:974-9. [DOI: 10.1016/j.dld.2014.07.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
262 Larsson G, Shenoy KT, Ramasubramanian R, Thayumanavan L, Balakumaran LK, Bjune GA, Moum BA. Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India. United European Gastroenterol J 2014;2:397-405. [PMID: 25360318 DOI: 10.1177/2050640614546947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
263 Khanna R, Bouguen G, Feagan BG, Dʼhaens G, Sandborn WJ, Dubcenco E, Baker KA, Levesque BG. A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohnʼs Disease: Recommendations for Clinical Trial Design. Inflammatory Bowel Diseases 2014;20:1850-61. [DOI: 10.1097/mib.0000000000000131] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
264 Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease. Journal of Crohn's and Colitis 2014;8:1022-9. [DOI: 10.1016/j.crohns.2014.01.029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
265 Swale A, Miyajima F, Roberts P, Hall A, Little M, Beadsworth MB, Beeching NJ, Kolamunnage-Dona R, Parry CM, Pirmohamed M. Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study. PLoS One 2014;9:e106118. [PMID: 25170963 DOI: 10.1371/journal.pone.0106118] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
266 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 139] [Article Influence: 17.8] [Reference Citation Analysis]
267 Bodelier AG, Pierik MJ, van den Heuvel T, Bovee-oudenhoven IM, de Boer E, Hameeteman W, Masclee AA, Jonkers D. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients. European Journal of Gastroenterology & Hepatology 2014;26:902-9. [DOI: 10.1097/meg.0000000000000141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
268 Guardiola J, Lobatón T, Rodríguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C, Sanjuan X, Sánchez E, Rodríguez-Moranta F. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12:1865-1870. [PMID: 24993368 DOI: 10.1016/j.cgh.2014.06.020] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 12.3] [Reference Citation Analysis]
269 Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, Chatelain D, Barre A, Nguyen-Khac E, Lantz O, Dupas JL, Treiner E. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol. 2014;176:266-274. [PMID: 24450998 DOI: 10.1111/cei.12277] [Cited by in Crossref: 201] [Cited by in F6Publishing: 208] [Article Influence: 25.1] [Reference Citation Analysis]
270 D’Incà R, Caccaro R. Measuring disease activity in Crohn’s disease: what is currently available to the clinician. Clin Exp Gastroenterol. 2014;7:151-161. [PMID: 24876789 DOI: 10.2147/ceg.s41413] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
271 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349-1362. [PMID: 24749763 DOI: 10.1111/apt.12749] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 15.8] [Reference Citation Analysis]
272 Yang X, Yu L, Yu W, Tang M, He C, Li Z, Liu Z. Intestinal wall thickness detected by multidetector spiral computed tomography enterography predicts the disease severity of Crohn's disease. Scand J Gastroenterol 2014;49:807-13. [PMID: 24730384 DOI: 10.3109/00365521.2014.907336] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
273 Magro F, Sousa P, Ministro P. C-reactive protein in Crohn's disease: how informative is it? Expert Rev Gastroenterol Hepatol. 2014;8:393-408. [PMID: 24635486 DOI: 10.1586/17474124.2014.893821] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
274 Schaffer T, Schoepfer AM, Seibold F; Swiss IBD Cohort Study Group. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity. J Crohns Colitis 2014;8:1125-32. [PMID: 24636141 DOI: 10.1016/j.crohns.2014.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
275 Kopylov U, Seidman EG. Role of capsule endoscopy in inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1155-1164 [PMID: 24574792 DOI: 10.3748/wjg.v20.i5.1155] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
276 Garg M, Burrell LM, Velkoska E, Griggs K, Angus PW, Gibson PR, Lubel JS. Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study. J Renin Angiotensin Aldosterone Syst 2015;16:559-69. [PMID: 24505094 DOI: 10.1177/1470320314521086] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
277 Novak KL, Panaccione R. Will Cross-Sectional Imaging Replace Endoscopy for Monitoring Response to Therapy in Crohn's Disease? Gastroenterology 2014;146:334-6. [DOI: 10.1053/j.gastro.2013.12.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
278 Roblin X, Cavaille A, Clavel L, Paul S. Intérêt des biomarqueurs dans la prise en charge des MICI. La Presse Médicale 2014;43:66-73. [DOI: 10.1016/j.lpm.2013.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
279 Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8:197-210. [PMID: 24345070 DOI: 10.1586/17474124.2014.869476] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
280 Sasaki T, Kunisaki R, Kinoshita H, Yamamoto H, Kimura H, Hanzawa A, Shibata N, Yonezawa H, Miyajima E, Sakamaki K. Use of color Doppler ultrasonography for evaluating vascularity of small intestinal lesions in Crohn’s disease: correlation with endoscopic and surgical macroscopic findings. Scand J Gastroenterol. 2014;49:295-301. [PMID: 24344807 DOI: 10.3109/00365521.2013.871744] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
281 Gerich ME, McGovern DP. Towards personalized care in IBD. Nat Rev Gastroenterol Hepatol. 2014;11:287-299. [PMID: 24345887 DOI: 10.1038/nrgastro.2013.242] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
282 Baxter VK, Shaw GC, Sotuyo NP, Carlson CS, Olson EJ, Zink MC, Mankowski JL, Adams RJ, Hutchinson EK, Metcalf Pate KA. Serum albumin and body weight as biomarkers for the antemortem identification of bone and gastrointestinal disease in the common marmoset. PLoS One 2013;8:e82747. [PMID: 24324827 DOI: 10.1371/journal.pone.0082747] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
283 Lobatón T, López-garcía A, Rodríguez-moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis 2013;7:e641-51. [DOI: 10.1016/j.crohns.2013.05.005] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 11.3] [Reference Citation Analysis]
284 Faubion WA, Fletcher JG, O'byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. American Journal of Gastroenterology 2013;108:1891-900. [DOI: 10.1038/ajg.2013.354] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 7.8] [Reference Citation Analysis]
285 Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut 2013;62:1806-16. [PMID: 24203056 DOI: 10.1136/gutjnl-2012-303957] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
286 Rogler G, Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: What does it mean? World J Gastroenterol 2013; 19(43): 7552-7560 [PMID: 24282345 DOI: 10.3748/wjg.v19.i43.7552] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
287 Falvey JD, Gearry RB, Day AS. Fecal calprotectin does not predict endoscopic remission in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:E80-E81. [PMID: 23619719 DOI: 10.1097/MIB.0b013e31828dc6d3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
288 Moniuszko A, Wiśniewska A, Rydzewska G. Biomarkers in management of inflammatory bowel disease. Prz Gastroenterol. 2013;8:275-283. [PMID: 24868269 DOI: 10.5114/pg.2013.38728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
289 Makanyanga JC, Taylor SA. Current and future role of MR enterography in the management of Crohn disease. AJR Am J Roentgenol. 2013;201:56-64. [PMID: 23789658 DOI: 10.2214/ajr.12.10406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
290 Makanyanga JC, Pendsé D, Dikaios N, Bloom S, Mccartney S, Helbren E, Atkins E, Cuthbertson T, Punwani S, Forbes A, Halligan S, Taylor SA. Evaluation of Crohn’s disease activity: Initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol 2014;24:277-87. [DOI: 10.1007/s00330-013-3010-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 8.8] [Reference Citation Analysis]
291 Papay P, Ignjatovic A, Karmiris K, Amarante H, Miheller P, Feagan B, D'haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel J, Panaccione R. Optimising monitoring in the management of Crohn's disease: A physician's perspective. Journal of Crohn's and Colitis 2013;7:653-69. [DOI: 10.1016/j.crohns.2013.02.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 7.7] [Reference Citation Analysis]
292 Berrill JW, Gallacher J, Hood K, Green JT, Matthews SB, Campbell AK, Smith A. An observational study of cognitive function in patients with irritable bowel syndrome and inflammatory bowel disease. Neurogastroenterol Motil. 2013;25:918-e704. [PMID: 23981191 DOI: 10.1111/nmo.12219] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
293 Bickelhaupt S, Froehlich JM, Cattin R, Patuto N, Tutuian R, Wentz KU, Culmann JL, Raible S, Bouquet H, Bill U. Differentiation between active and chronic Crohn’s disease using MRI small-bowel motility examinations - initial experience. Clin Radiol. 2013;68:1247-1253. [PMID: 23973163 DOI: 10.1016/j.crad.2013.06.024] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
294 Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212-221. [PMID: 23340060 DOI: 10.1097/mcg.0b013e3182732ff5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
295 Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev Clin Immunol. 2013;9:65-75; quiz 76. [PMID: 23256765 DOI: 10.1586/eci.12.86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
296 Rodríguez-moranta F, Lobatón T, Rodríguez-alonso L, Guardiola J. Calprotectina fecal en el diagnóstico de enfermedades inflamatorias. Gastroenterología y Hepatología 2013;36:400-6. [DOI: 10.1016/j.gastrohep.2012.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
297 Wang S, Wang Z, Shi H, Heng L, Juan W, Yuan B, Wu X, Wang F. Faecal calprotectin concentrations in gastrointestinal diseases. J Int Med Res. 2013;41:1357-1361. [PMID: 23723365 DOI: 10.1177/0300060513488499] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
298 Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013;38:44-51. [PMID: 23668698 DOI: 10.1111/apt.12335] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
299 Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A. When do we dare to stop biological or immunomodulatory therapy for Crohn’s disease? Results of a multidisciplinary European expert panel. J Crohns Colitis. 2013;7:820-826. [PMID: 23664620 DOI: 10.1016/j.crohns.2013.04.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
300 Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease. J Gastroenterol. 2014;49:638-645. [PMID: 23636735 DOI: 10.1007/s00535-013-0815-0] [Cited by in Crossref: 129] [Cited by in F6Publishing: 110] [Article Influence: 14.3] [Reference Citation Analysis]
301 Samson CM, Morgan P, Williams E, Beck L, Addie-Carson R, McIntire S, Booth A, Mendez E, Luzader C, Tomer G. Improved outcomes with quality improvement interventions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012;55:679-688. [PMID: 22699837 DOI: 10.1097/mpg.0b013e318262de16] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
302 Yang L, Ge Z, Gao Y, Li X, Dai J, Zhang Y, Xue H, Zhao Y. Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn's disease: Small bowel Crohn's disease. J Gastroenterol Hepatol 2013;28:829-33. [DOI: 10.1111/jgh.12146] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
303 Cury DB, Mizsputen SJ, Versolato C, Miiji LO, Pereira E, Delboni MA, Schor N, Moss AC. Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol 2013;282:66-70. [PMID: 23685388 DOI: 10.1016/j.cellimm.2013.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
304 Graff LA, Clara I, Walker JR, Lix L, Carr R, Miller N, Rogala L, Bernstein CN. Changes in fatigue over 2 years are associated with activity of inflammatory bowel disease and psychological factors. Clin Gastroenterol Hepatol. 2013;11:1140-1146. [PMID: 23602816 DOI: 10.1016/j.cgh.2013.03.031] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 7.3] [Reference Citation Analysis]
305 Lobatón T, Rodríguez-moranta F, Lopez A, Sánchez E, Rodríguez-alonso L, Guardiola J. A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:1034-42. [DOI: 10.1097/mib.0b013e3182802b6e] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 9.3] [Reference Citation Analysis]
306 Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U, Nally K, Peyrin-Biroulet L, Schoepfer A, Vatn M, Vavricka S. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7:670-677. [PMID: 23517932 DOI: 10.1016/j.crohns.2013.02.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
307 Bickelhaupt S, Pazahr S, Chuck N, Blume I, Froehlich JM, Cattin R, Raible S, Bouquet H, Bill U, Rogler G, Frei P, Boss A, Patak MA. Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin. Neurogastroenterol Motil. 2013;25:467-473. [PMID: 23495824 DOI: 10.1111/nmo.12088] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
308 De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal Healing in Crohnʼs Disease: A Systematic Review. Inflammatory Bowel Diseases 2013;19:429-44. [DOI: 10.1002/ibd.22977] [Cited by in Crossref: 107] [Cited by in F6Publishing: 99] [Article Influence: 11.9] [Reference Citation Analysis]
309 Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol 2012; 18(46): 6782-6789 [PMID: 23239916 DOI: 10.3748/wjg.v18.i46.6782] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
310 Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem. 2013;50:53-61. [PMID: 23129721 DOI: 10.1258/acb.2012.011272] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 6.3] [Reference Citation Analysis]
311 Büning C, Geissler N, Prager M, Sturm A, Baumgart DC, Büttner J, Bühner S, Haas V, Lochs H. Increased small intestinal permeability in ulcerative colitis: Rather genetic than environmental and a risk factor for extensive disease?: . Inflammatory Bowel Diseases 2012;18:1932-9. [DOI: 10.1002/ibd.22909] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.6] [Reference Citation Analysis]
312 Nakarai A, Kato J, Hiraoka S, Kuriyama M, Akita M, Hirakawa T, Okada H, Yamamoto K. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108:83-89. [PMID: 23007005 DOI: 10.1038/ajg.2012.315] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 6.5] [Reference Citation Analysis]
313 Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, Riestra S, de Francisco R, Papo M, Borruel N. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:762-769. [PMID: 22517240 DOI: 10.1097/meg.0b013e32835414b2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
314 Sherwood RA. Faecal markers of gastrointestinal inflammation. J Clin Pathol 2012;65:981-5. [DOI: 10.1136/jclinpath-2012-200901] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
315 Jung YS, Park JJ, Kim SW, Hong SP, Kim TI, Kim WH, Cheon JH. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. Dig Liver Dis 2012;44:897-903. [PMID: 22721842 DOI: 10.1016/j.dld.2012.05.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
316 Abraham BP, Kane S. Fecal Markers: Calprotectin and Lactoferrin. Gastroenterology Clinics of North America 2012;41:483-95. [DOI: 10.1016/j.gtc.2012.01.007] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 6.5] [Reference Citation Analysis]
317 Schoepfer AM, Vavricka S, Zahnd-straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: Clinical activity is judged to be more relevant than endoscopic severity or biomarkers. Journal of Crohn's and Colitis 2012;6:412-8. [DOI: 10.1016/j.crohns.2011.09.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
318 DuPont HL. Approach to the patient with infectious colitis. Curr Opin Gastroenterol. 2012;28:39-46. [PMID: 22080825 DOI: 10.1097/mog.0b013e32834d3208] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
319 Saurer L, Rihs S, Birrer M, Saxer-Seculic N, Radsak M, Mueller C. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1 in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. J Crohns Colitis. 2012;6:913-923. [PMID: 22410349 DOI: 10.1016/j.crohns.2012.02.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
320 af Björkesten C, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology 2012;47:528-37. [DOI: 10.3109/00365521.2012.660542] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 10.9] [Reference Citation Analysis]
321 D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224. [PMID: 22344983 DOI: 10.1002/ibd.22917] [Cited by in Crossref: 528] [Cited by in F6Publishing: 496] [Article Influence: 52.8] [Reference Citation Analysis]
322 van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis. 2012;18:2018-2025. [PMID: 22275341 DOI: 10.1002/ibd.22896] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
323 Shaoul R, Sladek M, Turner D, Paeregaard A, Veres G, Wauters GV, Escher J, Dias JA, Lionetti P, Staino A. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn’s disease. Inflamm Bowel Dis. 2012;18:1493-1497. [PMID: 22275268 DOI: 10.1002/ibd.21875] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
324 Buisson A, Chevaux JB, Bommelaer G, Peyrin-Biroulet L. Diagnosis, prevention and treatment of postoperative Crohn’s disease recurrence. Dig Liver Dis. 2012;44:453-460. [PMID: 22265329 DOI: 10.1016/j.dld.2011.12.018] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
325 Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-d'Elia H. Calprotectin in ankylosing spondylitis--frequently elevated in feces, but normal in serum. Scand J Gastroenterol. 2012;47:435-444. [PMID: 22229862 DOI: 10.3109/00365521.2011.648953] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
326 Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017. [PMID: 22223566 DOI: 10.1002/ibd.22863] [Cited by in Crossref: 127] [Cited by in F6Publishing: 122] [Article Influence: 12.7] [Reference Citation Analysis]
327 Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, Potamianos SP. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012;47:519-530. [PMID: 22200942 DOI: 10.1007/s00535-011-0516-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 7.0] [Reference Citation Analysis]
328 Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, Varga E, Szathmari M, Lakatos PL. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification? Inflamm Bowel Dis. 2012;18:1647-1654. [PMID: 22081542 DOI: 10.1002/ibd.21933] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
329 Zhou LF, Miao YL. Progress in research of biological activity markers for inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2011; 19(31): 3229-3236 [DOI: 10.11569/wcjd.v19.i31.3229] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
330 Baars JE, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18:1634-1640. [PMID: 22069022 DOI: 10.1002/ibd.21925] [Cited by in Crossref: 143] [Cited by in F6Publishing: 138] [Article Influence: 13.0] [Reference Citation Analysis]
331 Moleski SM, Choudhary C. Special considerations for women with IBD. Gastroenterol Clin North Am 2011;40:387-98, viii-ix. [PMID: 21601786 DOI: 10.1016/j.gtc.2011.03.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
332 Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484-498. [PMID: 21939926 DOI: 10.1016/j.crohns.2011.07.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
333 Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-1826. e2. [PMID: 21530748 DOI: 10.1053/j.gastro.2010.11.058] [Cited by in Crossref: 268] [Cited by in F6Publishing: 254] [Article Influence: 24.4] [Reference Citation Analysis]
334 Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M, Razaire S, de Lédinghen V, Zerbib F. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34:462-469. [PMID: 21671970 DOI: 10.1111/j.1365-2036.2011.04743.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 5.6] [Reference Citation Analysis]
335 Cámara RJ, Lukas PS, Begré S, Pittet V, von Känel R. Effects of social support on the clinical course of Crohnʼs disease: . Inflammatory Bowel Diseases 2011;17:1277-86. [DOI: 10.1002/ibd.21481] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
336 Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O, Høie O, Rydning A, Vatn MH. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol. 2011;46:1081-1091. [PMID: 21619483 DOI: 10.3109/00365521.2011.584897] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 7.3] [Reference Citation Analysis]
337 Díaz-Jiménez D, Núñez LE, Beltrán CJ, Candia E, Suazo C, Álvarez-Lobos M, González MJ, Hermoso MA, Quera R. Soluble ST2: A new and promising activity marker in ulcerative colitis. World J Gastroenterol 2011; 17(17): 2181-2190 [PMID: 21633527 DOI: 10.3748/wjg.v17.i17.2181] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
338 Benevento G, Avellini C, Terrosu G, Geraci M, Lodolo I, Sorrentino D. Diagnosis and assessment of Crohn's disease: the present and the future. Expert Rev Gastroenterol Hepatol. 2010;4:757-766. [PMID: 21108595 DOI: 10.1586/egh.10.70] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
339 Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol. 2011;46:694-700. [PMID: 21456899 DOI: 10.3109/00365521.2011.560680] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 5.3] [Reference Citation Analysis]
340 Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010;16:2131-6. [PMID: 20848462 DOI: 10.1002/ibd.21300] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 8.8] [Reference Citation Analysis]
341 Beniwal P, Harrell L. The status of diagnostic markers for inflammatory bowel disease. Curr Gastroenterol Rep. 2010;12:479-484. [PMID: 20890737 DOI: 10.1007/s11894-010-0145-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
342 Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478. [PMID: 20886319 DOI: 10.1007/s11894-010-0146-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
343 Lu H, Lian L, Navaneethan U, Shen B. Clinical utility of C-reactive protein in patients with ileal pouch anal anastomosis. Inflamm Bowel Dis 2010;16:1678-84. [PMID: 20186934 DOI: 10.1002/ibd.21239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
344 Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Dig Dis Sci 2011;56:1601-11. [PMID: 21203903 DOI: 10.1007/s10620-010-1494-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
345 Graff LA, Vincent N, Walker JR, Clara I, Carr R, Ediger J, Miller N, Rogala L, Rawsthorne P, Lix L, Bernstein CN. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1882-1889. [PMID: 21830266 DOI: 10.1002/ibd.21580] [Cited by in Crossref: 176] [Cited by in F6Publishing: 163] [Article Influence: 14.7] [Reference Citation Analysis]
346 Caccaro R, D’Incá R, Sturniolo GC. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:551-558. [PMID: 20594128 DOI: 10.1586/eci.10.26] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
347 Lakatos PL, Kiss LS, Palatka K, Altorjay I, Antal-Szalmas P, Palyu E, Udvardy M, Molnar T, Farkas K, Veres G, Harsfalvi J, Papp J, Papp M. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis. 2011;17:767-777. [PMID: 20865702 DOI: 10.1002/ibd.21402] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
348 Moein S, Qujeq D, Vaghari Tabari M, Kashifard M, Hajian-Tilaki K. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Caspian J Intern Med 2017;8:178-82. [PMID: 28932369 DOI: 10.22088/cjim.8.3.178] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
349 Matsuura R, Watanabe O, Nakamura M, Yamamura T, Matsushita M, Suhara H, Furukawa K, Ishikawa T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Hirooka Y, Goto H. Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings. Nagoya J Med Sci 2018;80:257-66. [PMID: 29915443 DOI: 10.18999/nagjms.80.2.257] [Cited by in F6Publishing: 1] [Reference Citation Analysis]